Related Experiment Video
Updated: Jul 13, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication
Insights
Thrombotic thrombocytopenic purpura (TTP) can cause myocardial injury, leading to significant mortality. Standard treatments for heart attacks are often ineffective for TTP patients.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder.
- Cardiac involvement in TTP is typically underreported, with myocardial injury and cardiogenic shock being exceptional.
Observation:
- This study analyzed 26 patients diagnosed with TTP and objective evidence of myocardial injury.
- Six patients presented with myocardial injury, none of whom had underlying coronary artery disease.
Findings:
- The affected patients (mean age 43.6 years, 66% female) showed elevated troponin, creatinine, and reduced hemoglobin levels.
- Half of the patients (50%) died during hospitalization, with one death attributed to ST-segment elevation myocardial infarction.
Implications:
- Myocardial injury is a frequent complication of TTP, associated with substantial mortality.
- Survivors may face long-term left ventricular dysfunction.
- Established therapies for myocardial ischemia show limited efficacy in TTP-related cardiac events.
Background:
Although thrombotic thrombocytopenic purpura (TTP) typically involves the heart, angina and myocardial injury are uncommonly reported; fatal cardiogenic shock is exceptional.
Methods:
We analyzed 26 patients with TTP who had objective evidence of myocardial injury.
Results:
Myocardial injury was evident in 6 patients. None had coronary disease. Mean age was 43.6 years; four patients (66%) were female. Mean troponin, creatinine and hemoglobin levels were 7.82 ng/dL (
Conclusions:
Myocardial injury frequently complicates the TTP syndrome and associated mortality is substantial. In survivors, enduring left ventricular failure is plausible. Widely accepted therapies for myocardial ischemia are not consistently efficacious in the setting of TTP.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Pericarditis I: Introduction
Transient Ischemic Attack l: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

